The global Glioblastoma Multiforme Treatment market size is expected to be worth around US$ 10.2 billion by 2030, according to a new report by Vision Research Reports.
The global Glioblastoma Multiforme Treatment market size was valued at US$ 5.14 billion in 2020 and is anticipated to grow at a CAGR of 12.8% during forecast period 2021 to 2030.
Growth Factors
The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy. In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years. The growing prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios are among the factors anticipated to fuel the market growth. The presence of a strong pipeline is expected to act as a major driver for the glioblastoma multiforme (GBM) treatment market during the forecast period.
Report Highlights
Radiation therapy dominated the market with a revenue share of 47.6% in 2020 owing to the improved survival rates. Radiation therapy can be recommended as the first treatment or combined with chemotherapy and surgery. It is also effective and highly recommended for brain tumors in case of recurrence. The use of temozolomide along with radiotherapy makes the tumor more sensitive to radiation. This combination of therapy is more effective than radiation without temozolomide.
The others segment accounted for the largest revenue share of 76.4% in 2020. The other drugs segment includes drugs such as everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA). Corticosteroids are mainly prescribed to reduce the peritumoral vasogenic edema for symptomatic benefits. Dexamethasone is mainly prescribed due to its lack of mineralocorticoid activity.
North America accounted for the largest share of 53.6% in 2020. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility of quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth.
Key Players
Merck & Co., Inc.
Amgen, Inc.
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Amgen, Inc.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Arbor Pharmaceuticals, LLC
Amneal Pharmaceuticals
Karyopharm Therapeutics, Inc.
Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
Report Coverage | Details |
Market Size | USD 10.2 Billion by 2030 |
Growth Rate | CAGR of 12.8% From 2021 to 2030 |
Base Year | 2020 |
Historic Data | 2017 to 2020 |
Forecast Period | 2021 to 2030 |
Segments Covered | Treatment, Drug class, End-use |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Mentioned | Merck & Co., Inc.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; Pfizer Inc.; Amgen, Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Arbor Pharmaceuticals, LLC; Amneal Pharmaceuticals; Karyopharm Therapeutics, Inc.; Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.) |
Market Segmentation
Treatment
Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Tumor Treating Field (TTF) Therapy
Immunotherapy
Drug Class
Temozolomide
Bevacizumab
Lomustine
Carmustine Wafers
Others
End-use
Hospitals
Clinics
Ambulatory Surgical Centers
Regional
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Russia
Asia Pacific
China
India
Japan
South Korea
Australia
Singapore
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
The Glioblastoma Multiforme Treatment market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Glioblastoma Multiforme Treatment market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Glioblastoma Multiforme Treatment market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Glioblastoma Multiforme Treatment market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Glioblastoma Multiforme Treatment market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Glioblastoma Multiforme Treatment capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Glioblastoma Multiforme Treatment by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Glioblastoma Multiforme Treatment market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Glioblastoma Multiforme Treatment market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Glioblastoma Multiforme Treatment market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Glioblastoma Multiforme Treatment industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
Glioblastoma Multiforme Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Glioblastoma Multiforme Treatment market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Glioblastoma Multiforme Treatment market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Glioblastoma Multiforme Treatment market. These factors have benefited the growth of the global market for Glioblastoma Multiforme Treatment. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Glioblastoma Multiforme Treatment. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Glioblastoma Multiforme Treatment are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Glioblastoma Multiforme Treatment Market, By Treatment
7.1. Glioblastoma Multiforme Treatment Market, by Treatment, 2021-2030
7.1.1. Surgery
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Radiation Therapy
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Chemotherapy
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Targeted Therapy
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Tumor Treating Field (TTF) Therapy
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Immunotherapy
7.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Glioblastoma Multiforme Treatment Market, By Drug Class
8.1. Glioblastoma Multiforme Treatment Market, by Drug Class, 2021-2030
8.1.1. Temozolomide
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Bevacizumab
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Lomustine
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Carmustine Wafers
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Glioblastoma Multiforme Treatment Market, By End User
9.1. Glioblastoma Multiforme Treatment Market, by End User, 2021-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Clinics
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Ambulatory Surgical Centers
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Glioblastoma Multiforme Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Treatment (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 11. Company Profiles
11.1. Merck & Co., Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Amgen, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. F. Hoffmann-La Roche Ltd.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Pfizer Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Amgen, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Teva Pharmaceutical Industries Ltd.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Sun Pharmaceutical Industries Ltd.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Arbor Pharmaceuticals, LLC
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Amneal Pharmaceuticals
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Karyopharm Therapeutics, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms